These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 12947154

  • 1. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
    Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J, Ortín R, Tirado I, Souto JC, Fontcuberta J.
    Stroke; 2003 Oct; 34(10):2387-91. PubMed ID: 12947154
    [Abstract] [Full Text] [Related]

  • 2. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.
    J Thromb Haemost; 2005 Oct; 3(10):2211-8. PubMed ID: 16092924
    [Abstract] [Full Text] [Related]

  • 3. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
    Santamaría A, Borrell M, Oliver A, Ortín R, Forner R, Coll I, Mateo J, Souto JC, Fontcuberta J.
    Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
    [Abstract] [Full Text] [Related]

  • 4. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke.
    Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J.
    Stroke; 2003 Apr 01; 34(4):1038-40. PubMed ID: 12649517
    [Abstract] [Full Text] [Related]

  • 6. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 01; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 7. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
    Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP.
    Thromb Haemost; 2002 Dec 01; 88(6):1020-5. PubMed ID: 12529754
    [Abstract] [Full Text] [Related]

  • 8. Dose-Response Relationship Between Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) and Stroke: A Chinese Case-Control Study.
    Dai H, Shi J, He Q, Sun H.
    Med Sci Monit; 2017 Sep 11; 23():4376-4381. PubMed ID: 28890533
    [Abstract] [Full Text] [Related]

  • 9. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.
    Rooth E, Wallen H, Antovic A, von Arbin M, Kaponides G, Wahlgren N, Blombäck M, Antovic J.
    Blood Coagul Fibrinolysis; 2007 Jun 11; 18(4):365-70. PubMed ID: 17473579
    [Abstract] [Full Text] [Related]

  • 10. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 11. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
    van Tilburg NH, Rosendaal FR, Bertina RM.
    Blood; 2000 May 01; 95(9):2855-9. PubMed ID: 10779431
    [Abstract] [Full Text] [Related]

  • 12. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J, Schulman S, Eelde A, Blombäck M.
    Haemophilia; 2001 Nov 01; 7(6):557-60. PubMed ID: 11851753
    [Abstract] [Full Text] [Related]

  • 13. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 01; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 14. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
    Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C.
    Arterioscler Thromb Vasc Biol; 2007 Apr 01; 27(4):955-62. PubMed ID: 17272741
    [Abstract] [Full Text] [Related]

  • 15. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors.
    Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC.
    Arterioscler Thromb Vasc Biol; 2000 Sep 01; 20(9):2156-61. PubMed ID: 10978263
    [Abstract] [Full Text] [Related]

  • 16. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Svenungsson E, Antovic A.
    Thromb Res; 2017 Oct 01; 158():168-173. PubMed ID: 28669410
    [Abstract] [Full Text] [Related]

  • 17. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 01; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 18. Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study.
    Monasterio J, Bermúdez P, Quiroga D, Francisco E, Meneses B, Montaner J.
    Pathophysiol Haemost Thromb; 2010 Oct 01; 33(5-6):382-6. PubMed ID: 15692248
    [Abstract] [Full Text] [Related]

  • 19. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
    Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Miyata S, Kawamura T, Horiuchi H, Fukumoto Y, Shimokawa H.
    Arterioscler Thromb Vasc Biol; 2016 Jun 01; 36(6):1293-301. PubMed ID: 27102961
    [Abstract] [Full Text] [Related]

  • 20. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
    Antovic JP, Rafik Hamad R, Antovic A, Blombäck M, Bremme K.
    Thromb Haemost; 2002 Oct 01; 88(4):644-7. PubMed ID: 12362237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.